Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug: M + nateglinide
Metformin‐sulphonylurea (second‐ or third‐generation) combination… showed no clear difference in M + nateglinide compared with metformin plus another antidiabetic drug (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug M + nateglinide Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes… (2019) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 233 participants | Very low |
Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug M + nateglinide Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes… (2019) · Cochrane Headline outcomes only | no estimate extracted | 3 studies · 874 participants | Low |
Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug M + nateglinide Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes… (2019) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 446 participants | Low |
Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug M + nateglinide Metformin‐sulphonylurea (second‐ or third‐generation) combination… showed no clear difference in M + nateglinide compared with metformin plus another antidiabetic drug (low certainty). Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes… (2019) · Cochrane Headline outcomes only | RR 1.68 [0.54, 5.21] | 3 studies · 874 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.